Grace Therapeutics, Inc.

Stage 4 · Declining · week 11

As of Oct 22, 2026, Grace Therapeutics is in Stage 4, the downtrend phase, now in week 11 (since Aug 11, 2026). It closed at $1.92, 62.6% below its 52-week high and below its 200-day average, which is falling.

Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. More about the company

$1.92

-2.54% today

$40.3M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is GRCE early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S2 15w

S2 20w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 9w → S1 8w → S4 4w → S1 6w → S2 12w → S3 10w → S2 2w → S3 2w → S4 7w → S1 4w → S2 15w → S3 4w → S4 9w → S1 11w → S2 7w → S3 10w → S2 20w → S3 4w → S4 9w → S1 1w → S4 10w current

Total tracked: 165 weeks across 21 stage runs.

GRCE among Biotechnology316th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…316	GRCEGrace Therapeutics, Inc.	Stage 4 · wk 11	28	−9.4%

vs 52W High

-62.6%

$1.88 lo$5.13 hi

62.6% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 11

1w13w26w

Week 11, established downtrend

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-33.1%

200 DMA: $2.87 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.76x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-9.4%

-17.6%

-18.3%

YTD

-47.5%

-39.0%

Scan Membership

Breakout Watch

Latest: 2024-11-06

10 appearances in last 60 days. First seen: 2018-10-26.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 11 · Vol 0.76x

2026-10-21S4

Wk 11 · Vol 0.60x

2026-10-20S4

Wk 10 · Vol 0.73x

2026-10-19S4

Wk 10 · Vol 0.69x

2026-10-16S4

Wk 10 · Vol 1.29x

2026-10-15S4

Wk 10 · Vol 0.77x

2026-10-14S4

Wk 10 · Vol 1.27x

2026-10-13S4

Wk 9 · Vol 0.37x

2026-10-12S4

Wk 9 · Vol 0.35x

2026-10-09S4

Wk 9 · Vol 0.26x

2026-10-08S4

Wk 9 · Vol 0.30x

2026-10-07S4

Wk 9 · Vol 0.46x

Moving averages & range

50 DMA

$2.10

200 DMA

$2.87

52W High

$5.13

52W Low

$1.88

5D Low

$1.88

Resistance levels (recent highs)

20d High

$2.15

60d High

$2.29

120d High

$2.69

250d High

$5.13

Next resistance

+12.0%

to 20d High

ROE

-36.2%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 0.6

Grace Therapeutics: quick answers

What stage is Grace Therapeutics in?

As of Oct 22, 2026, Grace Therapeutics (GRCE) is in Stage 4, the downtrend phase. It entered Stage 4 on Aug 11, 2026 and is in week 11. What the four stages mean

Is Grace Therapeutics in an uptrend?

No. Grace Therapeutics is in a Stage 4 downtrend. It trades 33.1% below its 200-day average, which is falling.

How far is Grace Therapeutics from its 52-week high?

Grace Therapeutics closed at $1.92 on Oct 22, 2026, 62.6% below its 52-week high of $5.13. Its 52-week low is $1.88.

How has Grace Therapeutics performed over the past year?

As of Oct 22, 2026, Grace Therapeutics is down 39.0% over the past year and down 47.5% so far in 2026.

Which sector and industry is Grace Therapeutics in?

Grace Therapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an injectable formulation developed to treat aneurysmal subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray of betamethasone to enhance neurological symptoms of Ataxia-Telangiectasia (A-T); and GTX-101, a topical bio adhesive film-forming bupivacaine spray for the treatment of pain associated with postherpetic neuralgia (PHN). The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. Grace Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.